Persistence of Adverse Drug Reaction-Related Hospitalization Risk Following Discharge.
adverse drug event
adverse drug reactions
hospital admission
medication errors
medication safety
risk factors
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
04 05 2022
04 05 2022
Historique:
received:
31
03
2022
revised:
25
04
2022
accepted:
29
04
2022
entrez:
14
5
2022
pubmed:
15
5
2022
medline:
18
5
2022
Statut:
epublish
Résumé
This retrospective cohort study analyzed the administrative hospital records of 91,500 patients with the aim of assessing adverse drug reaction (ADR)-related hospital admission risk after discharge from ADR and non-ADR-related admission. Patients aged ≥18 years with an acute admission to public hospitals in Tasmania, Australia between 2011 and 2015 were followed until May 2017. The index admissions (n = 91,550) were stratified based on whether they were ADR-related (n = 2843, 3.1%) or non-ADR-related (n = 88,707, 96.9%). Survival analysis assessed the post-index ADR-related admission risk using (1) the full dataset, and (2) a matched subset of patients using a propensity score analysis. Logistic regression was used to identify the risk factors for ADR-related admissions within 90 days of post-index discharge. The patients with an ADR-related index admission were almost five times more likely to experience another ADR-related admission within 90 days (p < 0.001). An increased risk persisted for at least 5 years (p < 0.001), which was substantially longer than previously reported. From the matched subset of patients, the risk of ADR-related admission within 90 and 365 days more than doubled in the patients with an ADR-related index admission (p < 0.0001). These admissions were often attributed to the same drug class as the patients’ index ADR-related admission. Cancer was a major risk factor for ADR-related re-hospitalization within 90 days; other factors included heart failure and increasing age.
Identifiants
pubmed: 35564982
pii: ijerph19095585
doi: 10.3390/ijerph19095585
pmc: PMC9101512
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Expert Opin Drug Saf. 2018 Dec;17(12):1185-1196
pubmed: 30540223
Br J Clin Pharmacol. 2010 Nov;70(5):749-55
pubmed: 21039769
Drug Saf. 2017 Jul;40(7):597-606
pubmed: 28382494
Pharmacoepidemiol Drug Saf. 2018 Nov;27(11):1281-1285
pubmed: 30264866
PLoS One. 2012;7(3):e33236
pubmed: 22438900
Drugs Aging. 2012 Mar 1;29(3):225-232
pubmed: 22372725
Drugs Aging. 2017 Oct;34(10):777-783
pubmed: 28952130
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Drug Saf. 2020 Jun;43(6):517-537
pubmed: 32125666
Eur J Clin Pharmacol. 2008 Jul;64(7):715-22
pubmed: 18385990
Br J Clin Pharmacol. 2014 Aug;78(2):202-17
pubmed: 24283967
BMJ. 2009 Jan 07;338:a2752
pubmed: 19129307
Public Health Res Pract. 2017 Apr 27;27(2):
pubmed: 28474053
Age Ageing. 2019 Dec 1;49(1):7-11
pubmed: 31665207
Drug Metab Rev. 2009;41(2):67-76
pubmed: 19514965
BMC Health Serv Res. 2013 Nov 12;13:473
pubmed: 24219303
Eur J Clin Pharmacol. 2017 Jun;73(6):759-770
pubmed: 28251277
Intern Med J. 2019 Jan;49(1):84-93
pubmed: 30281186
N Engl J Med. 2009 Oct 15;361(16):1521-3
pubmed: 19797277
Intern Med J. 2006 Apr;36(4):221-5
pubmed: 16640738
World Health Organ Tech Rep Ser. 1972;498:1-25
pubmed: 4625548
Eur J Clin Pharmacol. 2016 May;72(5):631-9
pubmed: 26884320